A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(12 sites)
United States
City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California Sarah Cannon Research Institute at HealthONE, Denver, Colorado Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, Maryland Massachusetts General Hospital, Boston, Massachusetts Dana-Farber Cancer Institute, Boston, Massachusetts Washington University School of Medicine (Siteman Cancer Center), St Louis, Missouri University of North Carolina at Chapel Hill, Chapel Hill, North Carolina Sarah Cannon Research Institute University of Oklahoma, Oklahoma City, Oklahoma Providence Portland Medical Center, Portland, Oregon The University of Texas, MD Anderson Cancer Center, Houston, Texas Mays Cancer Center / University of Texas, San Antonio, San Antonio, Texas NEXT Virginia, Fairfax, Virginia Last updated September 2025